- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02433977
The Effects of NOx and Conjugated Linoleic Acid on Asthmatics (NICLA)
April 5, 2021 updated by: Sally E. Wenzel MD, Gladwin, Mark, MD
A Proof of Concept Study to Determine the Effects of NOX and Conjugated Linoleic Acid on Asthmatics
This study will examine the hypothesis that in obese asthmatics; treatment with NOx + CLA is well tolerated, safe and will increase eNO while reducing airway oxidative stress.
Allied with this, the investigators will define whether supplementing with this bioactive mediator modifies the airway microbiome, and reduces airway inflammation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Obesity is an asthma comorbidity associated with increased severity, poor control, reduced steroid responsiveness and greater exacerbation and healthcare utilization rates.
These associations are not explained by having a greater degree of Th-2 inflammation.
Rather, the obese asthma phenotype defined in several cluster studies, has paradoxically reduced levels of Th-2 biomarkers, including sputum eosinophils and exhaled nitric oxide (NO).
The investigators previous research has shown that the inverse relation between increased body mass index (BMI) and reduced exhaled NO, may be explained by a metabolic imbalance characterized by lower L-arginine and greater asymmetric di-methyl arginine (ADMA) levels.
Having a low L-arginine/ADMA ratio has been shown to inhibit and uncouple all isoforms of nitric oxidase synthase (NOS), thereby reducing NO bioavailability and promoting oxidative stress through enhanced superoxide production.
In obese asthmatics, this imbalance not only correlates with exhaled NO, but also with lower FEV1% and poorer asthma-related quality of life.
Yet the effect of obesity in asthma is unlikely to be solely dependent on a single mechanism.
Other factors, such as increased Th1 and Th-17-mediated inflammation have been shown to occur in human and animal models.
Given all of these potential avenues, it is imperative that an intervention is sufficiently pleiotropic that can, in addition to restoring airway NO levels, also reduce other obesity-related non-Th2 mechanism of inflammation.
The investigators hypothesize that treatment with conjugated linolenic acid (CLA) + nitrate and nitrite (together known as NOx), will restore NO airway bioavailability, reduce oxidative stress and improve airway inflammation in obese asthmatics.
To test this hypothesis, the investigators propose a phase II pilot study in which obese asthmatics with metabolic syndrome, will be treated orally with CLA+NOx for 8 weeks, in an open label study design to assess pre to post-intervention changes in airway and systemic biomarkers, and to determine the effects on lung function and bronchial hyperresponsiveness.
Participants will undergo a pre and post intervention bronchoscopy.
The results obtained from this project will be greatly informative to our understanding of the obese - asthma pathophysiology and for the development of clinical trials to determine the potential benefit of this intervention in improving health outcomes.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- The University of Pittsburgh Asthma Institute at UPMC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adequate completion of informed consent process with written documentation
- Male and female patients, ≥ 18 - 65 yrs old
- Diagnosis of asthma: based on previous physician diagnosis and either baseline pre-bronchodilator FEV1 50% or greater predicted with a 12% or greater bronchodilator response to 4 puffs of albuterol or PC20 methacholine (16 mg) if no BD response.If the subject is not currently on an ICS/ ICS LABA, PC20 should be < 8 mg, if no BD response. Spirometry results within the prior 24 months located in the subject's medical records can be used to determine eligibility, if available.
- All racial/ethnic backgrounds with a diagnosis of asthma for ≥6 months
- Smoking history ≤10 pack years and no smoking in the last year
- BMI ≥ 30
- If subject is on ICS or ICS/LABA therapy- 30 days on a stable dose (up to 1,000 mcg daily fluticasone equivalent)
- Asthma diagnosed at age 9 or later
Exclusion Criteria:
- Respiratory tract infection within the last 4 weeks
- Oral or systemic CS burst within the last 4 weeks
- Asthma-related hospitalization within the last 2 months
- Asthma-related ER visit within the previous 4 weeks
- Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, diabetes
- Chronic renal failure (creatinine > 2.0) at screening (Associated with higher ADMA levels)
- Current statins use (statins lower ADMA levels), patients may stop and re-enroll after 2 weeks of stopping statins
- Positive pregnancy test
- Intolerance or allergy to the intervention drugs
- Current or recent (within 30 days) in an investigational treatment study.
- Unable or unlikely to complete study assessments or the study intervention (i.e. bronchoscopy) poses undue risk to patient in the opinion of the Investigator.
- Any kind of oral nitrates such as nitroglycerin or already taking supplements
- History of ICU admission/intubation due to asthma in the past year;
- More than three systemic corticosteroid requiring asthma exacerbations in the past year
- Systemic steroid dependent asthma (no daily oral steroids- short term therapy for asthma exacerbation is permitted)
- Use of mouthwash containing chlorhexidine (lowers NO) within 1 week prior to screening and throughout the study
- Untreated sleep apnea
- Hgb A1C ≥7
- Daily use of PPI's (Proton Pump Inhibitor) or H2 Blockers for GERD (it is permitted to take on an occasional basis- no more than 1x per week. If participants wash out of these meds for 1 week, they can enroll)
- Use of biologics for asthma/allergies unless there is a 4 month washout prior to enrollment (the washout for biologics is done for clinical reasons and not specifically for inclusion for the study).
- Drug and/or alcohol abuse for ≥1 year
- Breastfeeding
- Any other condition and/or situation that causes the investigator to deem a subject unsuitable for the study (e.g. due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Conjugated Linolenic Acid + NOx
This is a single arm study Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg) Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg) |
CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day
Other Names:
Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Exhaled NO Before and After Treatment
Time Frame: Before treatment at baseline and after treatment at 8 weeks
|
Determine how CLA and NOx affect airway NO bioavailability (exhaled NO)
|
Before treatment at baseline and after treatment at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarkers of Inflammation-bronchial Hyperresponsiveness Using PC20
Time Frame: Before treatment at baseline and after treatment at 8 weeks
|
To determine whether, compared to baseline, treatment with NOx + CLA can reduce bronchial hyperresponsiveness.
PC20 was measured by methacholine challenge (mg/mL) in three participants pre and post supplementation with Nitrate/Nitrite and cLA
|
Before treatment at baseline and after treatment at 8 weeks
|
Biomarkers of Inflammation- Concentration of Free CLA in Plasma
Time Frame: Before treatment at baseline and after treatment at 8 weeks
|
To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of free CLA in plasma
|
Before treatment at baseline and after treatment at 8 weeks
|
Number of Participants With an Increase in IL-6 and IL-1b Expression
Time Frame: Before treatment at baseline and after treatment at 8 weeks
|
To determine whether, compared to baseline, treatment with NOx + CLA will increase a participant's IL-6 and IL-1b expression.
|
Before treatment at baseline and after treatment at 8 weeks
|
Biomarkers of Inflammation-airway XO Activity
Time Frame: Before treatment at baseline and after treatment at 8 weeks
|
To determine whether, compared to baseline, treatment with NOx + CLA can effect airway XO activity determined in endobronchial biopsies
|
Before treatment at baseline and after treatment at 8 weeks
|
Biomarkers of Inflammation-15NO2-cLA
Time Frame: Before treatment at baseline and after treatment at 8 weeks
|
To determine whether, compared to baseline, treatment with NOx + CLA can effect measurement of 15NO2-cLA in urine.
|
Before treatment at baseline and after treatment at 8 weeks
|
Biomarkers of Inflammation-anion Superoxide
Time Frame: Before treatment at baseline and after treatment at 8 weeks
|
To determine whether, compared to baseline, treatment with NOx + CLA can decrease production of anion superoxide in fresh airway epithelial cells
|
Before treatment at baseline and after treatment at 8 weeks
|
Number of Participants With a Decrease of Inflammation Using Mitochondrial ROS Production
Time Frame: Before treatment at baseline and after treatment at 8 weeks
|
To determine whether, compared to baseline, treatment with NOx + CLA can decrease inflammation using mitochondrial ROS production in fresh and cultured airway epithelial cells.
|
Before treatment at baseline and after treatment at 8 weeks
|
Biomarkers of Inflammation- Concentration of NO2-CLA in Plasma
Time Frame: Before treatment at baseline and after treatment at 8 weeks
|
To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of NO2-cLA in plasma
|
Before treatment at baseline and after treatment at 8 weeks
|
Biomarkers of Inflammation- Concentration of NO2-CLA in Urine
Time Frame: Before treatment at baseline and after treatment at 8 weeks
|
To determine whether, compared to baseline, treatment with NOx + CLA can quantify the concentrations of NO2-cLA in urine
|
Before treatment at baseline and after treatment at 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sally E Wenzel, MD, The University of Pittsburgh Asthma Institute at UPMC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 1, 2015
Primary Completion (ACTUAL)
November 1, 2019
Study Completion (ACTUAL)
November 1, 2019
Study Registration Dates
First Submitted
December 11, 2014
First Submitted That Met QC Criteria
April 29, 2015
First Posted (ESTIMATE)
May 5, 2015
Study Record Updates
Last Update Posted (ACTUAL)
April 27, 2021
Last Update Submitted That Met QC Criteria
April 5, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO14110207
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Conjugated Linolenic Acid
-
University of Sao PauloUnknownAtherosclerosis | Morbid Obesity | Systemic InflammationBrazil
-
Aalborg University HospitalDanish Heart FoundationCompletedIschemic Stroke | Peripheral Artery Disease | Acute Myocardial Infarction
-
Hadassah Medical OrganizationIsrael Association of PediatriciansCompletedAttention Deficit Hyperactivity DisorderIsrael
-
Assistance Publique - Hôpitaux de ParisITERG; Institut Elevage; SAINT HUBERT; TERRES UNIVIA; TERRES INOVIACompletedCardiovascular Diseases | Inflammation | Metabolism Disorder, LipidFrance
-
Université de SherbrookeCompleted
-
University of Eastern FinlandKuopio University Hospital; VTT Technical Research Centre, FinlandCompleted
-
University of JenaCognis Deutschland GmbH & Co. KGCompleted
-
University of Wisconsin, MadisonCompleted
-
University of California, Los AngelesTerminated